1,3-二氯-6-甲氧基异喹啉 | 24623-39-0

• 物质功能分类: 医药中间体 - 杂环化合物 - 喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 中文名称: 1,3-二氯-6-甲氧基异喹啉
• 英文名称: 1,3-dichloro-6-methoxyisoquinoline
• 英文别名: 1,3-dichloro-6-methoxy-isoquinoline；1,3-Dichlor-6-methoxy-isochinolin
• CAS: 24623-39-0
• 化学式: C₁₀H₇Cl₂NO
• mdl: MFCD09258765
• 分子量: 228.078
• InChiKey: MDGSCLLECOTDSW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2933499090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1,3-Dichloro-6-methoxyisoquinoline
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1,3-Dichloro-6-methoxyisoquinoline
CAS number: 24623-39-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H7Cl2NO
Molecular weight: 228.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1,3-二氯-6-甲氧基异喹啉 在 四(三苯基膦)钯 作用下， 以 乙二醇二甲醚 、 乙醇 、 水 为溶剂， 反应 29.0h， 生成 6-methoxy-1,3-bis{4-[(4-dimethylaminobutyl)iminomethyl]phenyl}isoquinoline
  参考文献：
  名称：

  新的2,4-双[（取代的氨基甲基）苯基]喹啉，1,3-双[（取代的氨基甲基）苯基]异喹啉和2,4-双[（取代的氨基甲基）喹啉]的设计，合成和抗原生动物评价苯基]喹唑啉衍生物

  摘要：

  摘要 一系列新的2,4-双[（取代的氨基甲基）苯基]喹啉，1,3-双[（取代的氨基甲基）苯基]异喹啉和2,4-双[（取代的氨基甲基）苯基]喹唑啉衍生物设计，合成和体外针对三种原生动物寄生虫（恶性疟原虫，利什曼原虫donovani和布氏锥虫布鲁氏菌）进行了评估。生物学结果显示了抗原生动物活性，IC 50值在µM范围内。另外，用人类HepG2细胞评估了这些原始分子的体外细胞毒性。喹啉1c被鉴定为最有效的抗疟疾候选药物，对恶性疟原虫CQ敏感菌株3D7的细胞毒性与抗寄生虫活性之比为97 。喹唑啉3h也被确定为最有效的锥虫候选物，对布鲁氏布鲁氏菌菌株的选择性指数（SI）为43 。此外，由于恶性疟原虫和锥虫的端粒是这类氮杂环化合物的可能靶标，我们还通过FRET熔解法研究了最好的化合物对疟原虫和锥虫端粒G-四链体的稳定作用。

  DOI：

  10.1080/14756366.2019.1706502
• 作为产物：
  描述：

  1-chloro-6-methoxy-isoquinoline 2-oxide 在 三氯氧磷 作用下， 反应 3.0h， 以17%的产率得到1,3-二氯-6-甲氧基异喹啉
  参考文献：
  名称：

  WO2007/14920

  摘要：

  公开号：

文献信息

• [EN] HEPATITIS C VIRUS INHIBITORS<br/>[FR] INHIBITEURS DU VIRUS DE L'HEPATITE C
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2003099274A1

  公开（公告）日：2003-12-04

  Hepatitis C virus inhibitors are disclosed having the general formula:(I) wherein R1, R2, R3, R', B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds toinhibit HCV are also disclosed.

  丙型肝炎病毒抑制剂公开了具有以下通式：其中R1、R2、R3、R'、B、Y和X在描述中有所描述。还公开了包含该化合物的组合物以及使用该化合物抑制HCV的方法。
• Hepatitis C Virus Inhibitors
  申请人：Bachand Carol

  公开号：US20090202483A1

  公开（公告）日：2009-08-13

  The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

  本公开涉及化合物、组合物和治疗丙型肝炎病毒（HCV）感染的方法。还公开了含有这些化合物的药物组合物以及在治疗HCV感染中使用这些化合物的方法。
• Hepatitis C virus inhibitors
  申请人：——

  公开号：US20040106559A1

  公开（公告）日：2004-06-03

  Hepatitis C virus inhibitors are disclosed having the general formula: 1 wherein R 1 , R 2 , R 3 , R′, B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

  本文披露了具有以下一般式的丙型肝炎病毒抑制剂：1，其中R1、R2、R3、R'、B、Y和X在说明书中有描述。还披露了包含这些化合物的组合物和使用这些化合物抑制HCV的方法。
• MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS
  申请人：Simmen Kenneth Alan

  公开号：US20090281141A1

  公开（公告）日：2009-11-12

  Inhibitors of HCV replication of formula (I) and the N-oxides, salts, and stereoisomers thereof, wherein X is N, CH and where X bears a double bond it is C; R 1 is —OR 1 , —NH—SO 2 R 6 ; R 2 is hydrogen, and where X is C or CH, R 2 may also be C 1-6 alkyl; R 3 is hydrogen, C 1-6 alkyl, C 1-6 alkoxyC 1-6 alkyl, or C 3-7 cycloalkyl; R 4 is isoquinolinyl optionally substituted with one, two or three substituents each independently selected from C 1-6 alkyl, C 1-6 alkoxy, hydroxy, halo, polyhaloC 1-6 alkyl, polyhaloC 1-6 alkoxy, amino, mono- or diC 1-6 alkylamino, mono- or diC 1-6 alkylaminocarbonyl, C 1-6 alkylcarbonyl-amino, aryl, and Het; n is 3, 4, 5, or 6; each dashed line (represented by - - - - - ) represents an optional double bond; R 5 is hydrogen; aryl; Het; C 3-7 cycloalkyl optionally substituted with C 1-6 alkyl; or C 1-6 alkyl optionally substituted with C 3-7 cycloalkyl, aryl or with Het; R 6 is aryl; Het; C 3-7 cycloalkyl optionally substituted with C 1-6 alkyl; or C 1-6 alkyl optionally substituted with C 3-7 cycloalkyl, aryl or with Het; each aryl is phenyl optionally substituted with one, two or three substituents; and each Het is a 5 or 6 membered saturated, partially unsaturated or completely unsaturated heterocyclic ring containing 1 to 4 heteroatoms each independently selected from nitrogen, oxygen and sulfur, and being optionally substituted with one, two or three substituents; pharmaceutical compositions containing compounds (I) and processes for preparing compounds (I). Bioavailable combinations of the inhibitors of HCV of formula (I) with ritonavir are also provided.

  公式（I）及其N-氧化物，盐和立体异构体抑制HCV复制的抑制剂，其中X为N，CH，且X带有双键时为C; R1为—OR1，—NH—SO2R6; R2为氢，且当X为C或CH时，R2也可以是C1-6烷基; R3为氢，C1-6烷基，C1-6烷氧基C1-6烷基或C3-7环烷基; R4为异喹啉基，可选择地取代有一、两或三个取代基，每个取代基独立地选自C1-6烷基，C1-6烷氧基，羟基，卤素，多卤代C1-6烷基，多卤代C1-6烷氧基，氨基，一级或二级C1-6烷基氨基，一级或二级C1-6烷基氨基甲酰基，C1-6烷基甲酰氨基，芳基和Het; n为3、4、5或6;每个虚线（用- - - - -表示）表示可选的双键; R5为氢; 芳基; Het; C3-7环烷基，可选择地取代C1-6烷基; 或C1-6烷基，可选择地取代C3-7环烷基，芳基或与Het取代; R6为芳基; Het; C3-7环烷基，可选择地取代C1-6烷基; 或C1-6烷基，可选择地取代C3-7环烷基，芳基或与Het取代; 每个芳基为苯基，可选择地取代有一、两或三个取代基; 每个Het为含有1到4个杂原子的5或6元饱和，部分不饱和或完全不饱和的杂环，每个杂原子独立地选自氮，氧和硫，并可选择地取代有一、两或三个取代基; 包含化合物（I）的制药组合物以及制备化合物（I）的过程。还提供了公式（I）的抑制剂与利托那韦的生物利用度组合。
• MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS
  申请人：Simmen Kenneth Alan

  公开号：US20100120855A1

  公开（公告）日：2010-05-13

  Inhibitors of HCV replication of formula (I), the N-oxides, salts, and stereochemically isomeric forms thereof, wherein each dashed line (represented by represents an optional double bond; X is N, CH and where X bears a double bond it is C; R 1 is aryl or a saturated, a partially unsaturated or completely unsaturated 5 or 6 membered monocyclic or 9 to 12 membered bicyclic heterocyclic ring system wherein said ring system contains one nitrogen, and optionally one to three additional heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen, and wherein the remaining ring members are carbon atoms; wherein said ring system may be optionally substituted on any carbon or nitrogen ring atom with one, two, three, or four substituents; L is a direct bond, —O—, —O—C 1-4 alkanediyl-, —O—C(═O)—, —O—C(═O)—NR 4a — or —O—C(═O)—NR 4a C 1-4 alkanediyl-; R 2 is hydrogen, —OR 5 , —C(O)OR 5 , —C(═O)R 6 , —C(═O)NR 4a R 4b , —C(═O)NHR 4c , —NR 4a R 4b , —NHR 4c , —NR 4a SO p NR 4a R 4b , —NR 4a SO p R 7 , or B(OR 5 ) 2 ; R 3 is hydrogen, and where X is C or CH, R 3 may also be C 1-6 alkyl; n is 3, 4, 5, or 6; p is 1 or 2; aryl is phenyl, naphthyl, indanyl, or 1,2,3,4-tetrahydronaphthyl, each of which may be optionally substituted with one, two or three substituents; Het is a 5 or 6 membered saturated, partially unsaturated or completely unsaturated heterocyclic ring containing 1 to 4 heteroatoms each independently selected from nitrogen, oxygen and sulfur, being optionally condensed with a benzene ring, and wherein the group Het as a whole may be optionally substituted with one, two or three substituents; pharmaceutical compositions containing compounds (I) and processes for preparing compounds (I). Bioavailable combinations of the inhibitors of HCV of formula (I) with ritonavir are also provided.

  公式（I）的HCV复制抑制剂，其中N-氧化物，盐和立体化学异构体，其中每个虚线（由表示，表示可选的双键; X是N，CH，其中X带有双键，则为C; R1是芳基或饱和，部分不饱和或完全不饱和的5个或6个成员的单环或9至12个成员的双环杂环环系，其中所述环系含有一个氮，并且可选地含有一个至三个选自氧，硫和氮的群组的其他杂原子，其中剩余的环成员是碳原子;其中所述环系可以在任何碳或氮环原子上选择一个，两个，三个或四个取代基; L是直接键，-O-，-O-C1-4烷二基，-O-C（=O）-，-O-C（=O）-NR4a-或-O-C（=O）-NR4aC1-4烷二基; R2是氢，-OR5，-C（O）OR5，-C（=O）R6，-C（=O）NR4aR4b，-C（=O）NHR4c，-NR4aR4b，-NHR4c，-NR4aSOpNR4aR4b，-NR4aSOpR7或B（OR5）2; R3是氢，其中X是C或CH时，R3也可以是C1-6烷基; n为3、4、5或6; p为1或2;芳基是苯基，萘基，茚基或1,2,3,4-四氢萘基，每个都可以选择性地用一个，两个或三个取代基取代; Het是一个5个或6个成员的饱和，部分不饱和或完全不饱和的杂环环，其中每个独立选择自氮，氧和硫的1至4个杂原子，可选择地与苯环缩合，并且整个Het基团可以选择性地用一个，两个或三个取代基取代;含有化合物（I）的制药组合物和制备化合物（I）的过程也提供。还提供了公式（I）的HCV抑制剂与利托那韦的生物利用度组合。